8 June 2016 - CADTH has received notice of pending submissions from Daiichi Sankyo for edoxaban tosylate.

The submissions for edoxaban tosylate are for its use for the treatment of patients with non-valvular atrial fibrillation and for the prevention of stroke and systemic embolism.  The submissions are due on 7 July 2016.

For more details, go to: https://www.cadth.ca/edoxaban?utm_source=%2ALIVE%2A+CADTH%2FACMTS+Confirmed+Subscribers&utm_campaign=e6c1f3d192-Call-for-PI-Edoxaban-6-7-2016&utm_medium=email&utm_term=0_2e3705996c-e6c1f3d192-262951505